These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. [Administering GnRH Agonists in the luteal phase of Artificial Cycle Frozen-Thawed Embryo Transfers. A prospective randomized study]. Gogce M; Benchaib M; Hadj S; Bordes A; du Menildot P; Lornage J; Salle B Gynecol Obstet Fertil; 2015 Nov; 43(11):728-34. PubMed ID: 26297156 [TBL] [Abstract][Full Text] [Related]
45. Analogs of GnRH-I and GnRH-II inhibit epidermal growth factor-induced signal transduction and resensitize resistant human breast cancer cells to 4OH-tamoxifen. Günthert AR; Gründker C; Olota A; Läsche J; Eicke N; Emons G Eur J Endocrinol; 2005 Oct; 153(4):613-25. PubMed ID: 16189183 [TBL] [Abstract][Full Text] [Related]
46. [GnRH analogs versus gestagens in therapy of endometriosis]. Wenzl R; Schurz B; Freude G; Huber J Gynakol Geburtshilfliche Rundsch; 1993; 33(4):269-70. PubMed ID: 8130666 [No Abstract] [Full Text] [Related]
47. Phosphatase and tensin homolog gene inhibits the effect induced by gonadotropin-releasing hormone subtypes in human endometrial carcinoma cells. Zhao LJ; Liu N; Li XP; Wang JL; Wei LH Chin Med J (Engl); 2010 May; 123(9):1170-5. PubMed ID: 20529558 [TBL] [Abstract][Full Text] [Related]
48. More basic isoforms of serum gonadotropins during gonadotropin-releasing hormone agonist therapy in pubertal children. Wide L; Albertsson-Wikland K; Phillips DJ J Clin Endocrinol Metab; 1996 Jan; 81(1):216-21. PubMed ID: 8550754 [TBL] [Abstract][Full Text] [Related]
50. Which luteal phase support is better for each IVF stimulation protocol to achieve the highest pregnancy rate? A superiority randomized clinical trial. Gizzo S; Andrisani A; Esposito F; Noventa M; Di Gangi S; Angioni S; Litta P; Gangemi M; Nardelli GB Gynecol Endocrinol; 2014; 30(12):902-8. PubMed ID: 25268567 [TBL] [Abstract][Full Text] [Related]
51. [Modern tendencies in treatment of atypical glandular hyperplasia--our and foreign experience]. Ivanov S; Kovachev E; Tsonev A; Abbud A Akush Ginekol (Sofiia); 2010; 49(2):47-9. PubMed ID: 20734678 [TBL] [Abstract][Full Text] [Related]
52. [Comparative study of the efficiency of gonadotrope releasing hormone (GnRH) analogs for the treatment of endometriosis]. Keresztúri A; Daru J; Pál A Orv Hetil; 2002 Jun; 143(24):1475-8. PubMed ID: 12138645 [TBL] [Abstract][Full Text] [Related]
53. Effect of GnRHa ovulation trigger dose on follicular fluid characteristics and granulosa cell gene expression profiles. Vuong TNL; Ho MT; Ha TQ; Jensen MB; Andersen CY; Humaidan P J Assist Reprod Genet; 2017 Apr; 34(4):471-478. PubMed ID: 28197932 [TBL] [Abstract][Full Text] [Related]
54. GnRH antagonist versus long GnRH agonist protocol in poor IVF responders: a randomized clinical trial. Prapas Y; Petousis S; Dagklis T; Panagiotidis Y; Papatheodorou A; Assunta I; Prapas N Eur J Obstet Gynecol Reprod Biol; 2013 Jan; 166(1):43-6. PubMed ID: 23020996 [TBL] [Abstract][Full Text] [Related]
55. [Gonadotropin releasing hormone agonists in the treatment of adenomyosis with infertility]. Lin J; Sun C; Li R Zhonghua Fu Chan Ke Za Zhi; 1999 Apr; 34(4):214-6. PubMed ID: 11326917 [TBL] [Abstract][Full Text] [Related]
56. Time to menarche and final height after histrelin implant treatment for central precocious puberty. Gillis D; Karavani G; Hirsch HJ; Strich D J Pediatr; 2013 Aug; 163(2):532-6. PubMed ID: 23485026 [TBL] [Abstract][Full Text] [Related]
57. Management of Endometrial Hyperplasia With a Levonorgestrel-Releasing Intrauterine System: A Korean Gynecologic-Oncology Group Study. Kim MK; Seong SJ; Kim JW; Jeon S; Choi HS; Lee IH; Lee JH; Ju W; Song ES; Park H; Ryu HS; Lee C; Kang SB Int J Gynecol Cancer; 2016 May; 26(4):711-5. PubMed ID: 26905333 [TBL] [Abstract][Full Text] [Related]
58. [Use of decapeptyl (GnRH agonist) in the program of in vitro fertilization]. Leonov BV; Lukin VA; Moskalenko NV; Lazarev AP; Pulina GA; Khil'kevich LV; Iavorovskaia KA Akush Ginekol (Mosk); 1990 Jan; (1):48-51. PubMed ID: 2141239 [No Abstract] [Full Text] [Related]
59. Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty. Carel JC; Blumberg J; Seymour C; Adamsbaum C; Lahlou N; Eur J Endocrinol; 2006 Jan; 154(1):119-24. PubMed ID: 16382000 [TBL] [Abstract][Full Text] [Related]
60. The management of endometrial hyperplasia: an evaluation of current practice. Clark TJ; Neelakantan D; Gupta JK Eur J Obstet Gynecol Reprod Biol; 2006 Apr; 125(2):259-64. PubMed ID: 16246481 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]